"CytoDyn believes four weeks of leronlimab treatment to be sufficient to calm the cytokine storm..."
Four weeks of storm? Hmmmmm...
It is not easy to find CD12 Trial results published. Company website does not seem to help it's own case by much either...
"Amongst all patients in mITT, the primary endpoint (all-cause mortality at Day 28) was not statistically significant. When age adjustment was conducted, the primary endpoint was much closer to statistically significant value."
"With the age adjustment analysis in all other major secondary endpoints, there was consistent numerical superiority over the placebo group, with some secondary endpoints approaching statistical significance."
Ok, enough of Coronavirus.